Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.8.0.1
Significant Accounting Policies (Details Narrative)
12 Months Ended
Aug. 08, 2015
USD ($)
Mar. 09, 2015
USD ($)
Dec. 31, 2017
USD ($)
Breathlyzers
Dec. 31, 2016
USD ($)
Allowances for doubtful accounts for trade receivables     $ 596,196 $ 1,010,196
Bad debt expenses     494,436 146,196
Reversal of allowance for bad debts expense - related party       1,299,609
Allowance for bad debts for external party       146,195
Accounts receivable, related parties     570,800
Deferred revenue     126,471 41,120
Revenue recognition rebates expense     372,664 471,949
Shipping, handling and transportation costs     62,049 54,928
Cost of net revenue     $ 136,145 138,662
Percentage for deferred tax balances valuation allowance     100.00%  
Hainan Savy Akers Biosciences, Ltd. [Member]        
Contributed capital $ 64,091 $ 64,675    
Ownership percentage   19.90%    
Patents [Member]        
Number of patents | Breathlyzers     10  
Trade Receivable [Member] | Three Customers [Member]        
Concentration risk percentage     62.00%  
Concentration risk, number of customer | Breathlyzers     3  
Related Party [Member]        
Allowances for doubtful accounts for trade receivables       864,000
Fulton Bank of New Jersey [Member]        
Cash     $ 426,927 67,865
Bank of America [Member]        
Cash     7,915 795
PayPal [Member]        
Cash     $ 3,590 $ 4,040
Minimum [Member]        
Normal credit terms extended to customers     30 days  
Maximum [Member]        
Normal credit terms extended to customers     90 days  
Cash, FDIC insured amount     $ 250,000  
Maximum [Member] | Patents [Member]        
Finite-lived intangible asset, useful life     17 years